New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2013
10:30 EDTSNY, NVOSanofi advances after FDA delays rival insulin product
Sanofi (SNY) is climbing after the FDA decided that rival Novo Nordisk (NVO) would have to carry out a new study on its insulin product, Tresiba, before the product could be approved in the U.S. Sanofi's Lantus insulin competes with Tresiba, which has already been approved in Europe and Japan. Both Lantus and Tresiba are long acting insulin products, but Tresiba is effective for a longer time period and can be dosed more effectively, Novo has stated. The FDA required a new study to assess the effects of Tresiba on the heart before the product could be approved in the U.S. The study results probably won’t be reported before 2015, Novo said. In mid-morning trading, Sanofi advanced 90c, or 2%, to $47.40, while Novo Nordisk tumbled $26, or 13.50%, to $166.50.
News For SNY;NVO From The Last 14 Days
Check below for free stories on SNY;NVO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
06:18 EDTSNYSanofi, MyoKardia announce collaboration
Subscribe for More Information
September 16, 2014
07:33 EDTSNYMylan initiates Phase III clinical trials for Advair Diskus and Lantus
Mylan (MYL) announced it is initiating Phase III clinical trials for its generic version of GlaxoSmithKline's (GKS) Advair Diskus and its insulin analog to Sanofi's (SNY) Lantus. In October Mylan will commence a Phase III clinical trial to evaluate the equivalence of its product to Advair Diskus when administered by inhalation in adult asthma patients.
07:31 EDTNVOEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
September 12, 2014
10:04 EDTSNYSanofi unit granted orphan status for treatment of Gaucher disease
Subscribe for More Information
September 11, 2014
17:12 EDTNVONovo Nordisk Saxenda receives positive 14-1 vote in favor of approval from FDA
Subscribe for More Information
07:31 EDTNVOFDA Endocrinologic and Metabolic Drugs Advisory Committee to hold a meeting
Subscribe for More Information
05:27 EDTSNYGenzyme announces positive interim results from Lemtrada extension study
Subscribe for More Information
September 10, 2014
11:06 EDTNVOHigh option volume stocks
Subscribe for More Information
07:09 EDTSNYAmericas Committee for Treatment & Research in MS to hold a meeting
Subscribe for More Information
September 9, 2014
12:46 EDTNVONovo Nordisk weight loss drug helped people get thinner, Bloomberg reports
Subscribe for More Information
September 8, 2014
14:16 EDTSNYSanofi announces FDA approval of Menactra vaccine
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use